Filter
Reset all

Subjects

Content Types

Countries

Data access

Data access restrictions

Database access

Database licenses

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

PID systems

Provider types

Quality management

Repository languages

Software

Repository types

Versioning

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 4 result(s)
<<<!!!<<< This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information. Please go to www.ahrq.gov for current information. >>>!!!>>> HIV and AIDS Costs and Use is the first major research effort to collect information on a nationally representative sample of people in care for HIV infection. Also called the HIV Cost and Services Utilization Study (HCSUS), the core study is meant to help policymakers in the U.S. make informed decisions on the subject. The study describes the type of therapies available and costs of health care services for people with HIV/AIDS, as well as quality of care, social support, and non-medical services HIV/AIDS patients receive. Supplemental studies examine HIV care delivery in rural areas, prevalence of mental and substance abuse disorders, and other health issues of HIV/AIDS patients.
>>>!!!<<<2019-02-19: The repository is no longer available>>>!!!<<< >>>!!!<<<Data is archived at ChemSpider https://www.chemspider.com/Search.aspx?dsn=UsefulChem and https://www.chemspider.com/Search.aspx?dsn=Usefulchem Group Bradley Lab >>>!!!<<< see more information at the Standards tab at 'Remarks'
The COVID-19 pandemic has affected every country in the world. It is well documented that those most susceptible to the worst outcomes of COVID-19 are the immunocompromised and those with underlying comorbidities. Therefore, patients requiring treatment for COVID-19 will also be on additional medication, posing a risk for drug-drug interactions (DDIs). In order to address this, the Liverpool Drug Interactions website team developed this freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of COVID-19 and commonly prescribed co-medications.